Glenmark Pharma receives USFDA approval for generic ointment production
DSIJ Intelligence / 23 Aug 2017
Glenmark, a global pharmaceutical company that is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs), has a portfolio of 122 products authorised for distribution in the US market and 64 ANDA approvals pending with the USFDA.
The United States Food & Drug Administration (USFDA) has granted approval to Glenmark Pharmaceuticals Inc., for the production of Triamcinolone Acetonide Ointment USP, 0.1%, the generic version of Kenalog Ointment, 0.1% of Mylan Pharmaceuticals Inc. According to IMS’ health sales data for the 12-month period ending June 2017, Kenalog Ointment 0.1% achieved annual sales of approximately USD 26.3 million.
Glenmark, a global pharmaceutical company that is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs), has a portfolio of 122 products authorised for distribution in the US market and 64 ANDA approvals pending with the USFDA. The company has a presence in India, United States, Latin America, Europe and Rest of the World (ROW).
Meanwhile, the company’s stock ended in the negative, gaining 1.43% at Rs 610 per share on the BSE. On the NSE it attracted a total traded volume of 7,85,205 shares and a traded value of Rs 4,707.46 lakhs.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.